SCM
QNCX icon

Squadron Capital Management’s Quince Therapeutics QNCX Stock Holding History

Squadron Capital Management’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$734K Buy
+40,375
New +$928K 0.23% 38

Other funds holding QNCX

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Squadron Capital Management's QNCX Position: Q2 2026 in Review

Squadron Capital Management opened a new position in Quince Therapeutics (QNCX) in Q2 2026: 40,375 shares worth $734K. The stake represents 0.23% of the portfolio and ranks #38 among its holdings.

25 funds tracked by Wall St. Rank hold QNCX as of Q2 2026.

  • Squadron Capital Management held 40,375 shares of Quince Therapeutics worth $734K as of Q2 2026.
  • Quince Therapeutics was a new Squadron Capital Management position in Q2 2026.
  • Quince Therapeutics made up 0.23% of Squadron Capital Management's portfolio in Q2 2026, its #38 holding.
  • 25 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on Squadron Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.